Gastric Cancer
Conditions
Keywords
Distal Gastric Cancer, Gastrectomy, Metastasectomy
Brief summary
Our study aims to compare the efficacy and safety of Chemotherapy Alone Versus D2 distal gastrectomy and metastasectomy plus Chemotherapy for gastric cancer (GC) with one non-curable Factor
Detailed description
Gastric cancer is the fourth most common malignancy worldwide and the second leading cause of cancer-related deaths, with the highest mortality rates reported in East Asia, including China. Many patients are diagnosed at an advanced stage of gastric cancer because of late onset and nonspecific symptoms. The prognosis of patients with advanced gastric cancer with non-curable factors, such as hepatic, peritoneal, or distant lymph node metastases, is poor. Chemotherapy is the standard of care for these patients. Palliative resection or bypass surgery is generally indicated in the presence of major symptoms such as bleeding or obstruction for incurable advanced gastric cancer. The usefulness of gastrectomy and metastasectomy is still unclear. The REGATTA trial is the first clinical trial to explore the significance of surgery for incurable advanced gastric cancer. However, it concluded an opposite conclusion that gastrectomy followed by chemotherapy did not show any survival benefit compared with chemotherapy alone in advanced gastric cancer with a single non-curable factor. Interestingly, there was a significant interaction between treatment effect and tumor location in subgroup analyses of overall survival. Gastrectomy plus chemotherapy was associated with significantly worse overall survival in patients with upper-third tumors for less chemotherapy cycles. This finding raises the question whether inclusion criteria were restricted to the patients with lower-third tumor, findings of study might have been positive. So we raise this new trail to assess the significance of Gastrectomy and Metastasectomy for Distal Gastric Cancer With One Non-curable Factor.
Interventions
PROCEDUREsurgery
D2 gastrectomy + metastasectomy
DRUGchemotherapy
capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old. 2. PS (ECOG) of 0 or 1. 3. Without any other malignancies. 4. Written informed consent from the patient. 5. Standard gastrectomy with D2 lymphadenectomy for primary cancer 6. A single non-curable factor was defined by preoperative CT : hepatic metastasis (H1 or H2; maximum diameter ≤4 cm, number ≤4); peritoneal metastasis (R0 or R1 resection) para-aortic lymph node metastasis （number ≤4) ovarian metastasis adrenal metastasis renal metastasis 7. No contraindications to chemotherapy, including normal peripheral blood routine, liver and kidney function and electrocardiogram （WBC≥4.0 x 109 /L, NEU≥1.5 x 109 /L,PLT≥100 x 109 /L and HGB≥90g/L)
Exclusion criteria
1. Female in pregnancy or lactation. 2. Supraclavicular lymph nodes metastases，lung and bone metastases. 3. Massive ascites or cachexia. 4. Extensive cancer metastases of liver, peritoneal metastasis,para-aortic lymph node 5. Patients participating in any other clinical trails currently，or participated in other trails within 1 months. 6. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases. 7. Poor treatment compliance of patients 8. The group of chemotherapy alone accepts gastrectomy for bleeding or obstruction 9. Failure of R0 or R1 metastasectomy and gastrectomy with D2 lymphadenectomy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 5-year | OS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | 3-year | PFS |
Countries
China
Contacts
Primary ContactDazhi Xu, PHD
Outcome results
None listed